Pfizer Inc. (PFE) Position Boosted by Toronto Dominion Bank

Toronto Dominion Bank increased its position in Pfizer Inc. (NYSE:PFE) by 23.9% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,109,652 shares of the biopharmaceutical company’s stock after acquiring an additional 407,437 shares during the period. Toronto Dominion Bank’s holdings in Pfizer were worth $70,853,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Northstar Group Inc. grew its position in Pfizer by 0.4% in the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares during the period. Peregrine Asset Advisers Inc. grew its position in Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares during the period. Northwest Quadrant Wealth Management LLC grew its position in Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 50 shares during the period. River Wealth Advisors LLC grew its position in Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 55 shares during the period. Finally, Meridian Wealth Management LLC grew its position in Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares during the period. Institutional investors own 69.89% of the company’s stock.

A number of equities research analysts have commented on PFE shares. BMO Capital Markets set a $37.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 10th. ValuEngine raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Friday, October 6th. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Morgan Stanley raised shares of Pfizer from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $35.00 to $39.00 in a research report on Wednesday, September 20th. Finally, Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $38.77.

Shares of Pfizer Inc. (NYSE:PFE) traded up $0.68 during mid-day trading on Friday, hitting $37.14. 12,524,254 shares of the stock were exchanged, compared to its average volume of 19,888,109. Pfizer Inc. has a 12-month low of $30.90 and a 12-month high of $36.89. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.15 and a current ratio of 1.43. The company has a market cap of $218,400.30, a P/E ratio of 14.66, a price-to-earnings-growth ratio of 2.59 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter in the previous year, the firm posted $0.61 EPS. The company’s revenue for the quarter was up .9% compared to the same quarter last year. sell-side analysts expect that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s payout ratio is 79.01%.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Insiders own 0.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.thelincolnianonline.com/2017/12/15/pfizer-inc-pfe-position-boosted-by-toronto-dominion-bank.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply